<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03436979</url>
  </required_header>
  <id_info>
    <org_study_id>06-CLP-0098</org_study_id>
    <nct_id>NCT03436979</nct_id>
  </id_info>
  <brief_title>The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse</brief_title>
  <official_title>The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse Post-Market Surveillance Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pop Medical Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pop Medical Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the long term safety, durability of clinical
      effectiveness and cost effectiveness of the NeuGuide™ system when used for vaginal colpopexy
      in the treatment of uterine prolapse.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with POP-Q C point is &gt; 0 cm, the patient is satisfied with the outcome of the vaginal colpopexy performed using the NeuGuide™device, and there is no further surgical therapy for uterine prolapse.</measure>
    <time_frame>12 months</time_frame>
    <description>Primary composite performance outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of device / procedure related Serious Adverse Events (SAE).</measure>
    <time_frame>30 days</time_frame>
    <description>Primary safety of surgical implantation as reflected by adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of Serious Adverse Events and Adverse Events.</measure>
    <time_frame>12 months</time_frame>
    <description>Primary safety of NeuGuide treatment as reflected by adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean POP-Q C point score from baseline (cm).</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary anatomical performance of the NeuGuide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean POP-Q C point score from baseline (cm).</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary anatomical performance of the NeuGuide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean POP-Q C point score from baseline (cm).</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary anatomical of the NeuGuide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean POP-Q C point score from baseline (cm).</measure>
    <time_frame>24 months</time_frame>
    <description>Secondary anatomical performance of the NeuGuide treatment outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean POP-Q C point score from baseline (cm).</measure>
    <time_frame>36 months</time_frame>
    <description>Secondary anatomical performance of the NeuGuide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who require surgical therapy of uterine prolapse or urinary incontinence.</measure>
    <time_frame>3 years</time_frame>
    <description>Secondary performance: durability of the NeuGuide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects in whom the primary symptomatic reason for repair of prolapse persists.</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary symptomatic performance of the NeuGuide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time utilization of staff performing the NeuGuide procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary outcome: Cost performance of the procedure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Uterine Prolapse Without Vaginal Wall Prolapse</condition>
  <arm_group>
    <arm_group_label>Subjects</arm_group_label>
    <description>Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuGuide™ System</intervention_name>
    <description>The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.</description>
    <arm_group_label>Subjects</arm_group_label>
    <other_name>transvaginal sacrospinous ligament fixation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are undergoing surgical treatment for uterine prolapse.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with POP-Q C point ≥ 0 cm (stage II or greater) and anterior and posterior
             compartment prolapse with POP-Q Ba and Bp points &lt; (-)1 cm (stage I prolapse, measured
             after manual reduction of the cervix to the level of the ischial spines to avoid
             over-reduction).

          2. Patient planned for elective uterine prolapse surgical procedure.

          3. Non-pregnant female (female of child bearing potential must have a negative pregnancy
             test).

          4. Patient understands the nature and potential hazards of the procedure and provides
             written informed consent prior to any study specific assessments.

          5. Patient is able to complete written questionnaires.

          6. Patient is willing and able to comply with the specified study requirements and
             follow-up assessments, and can be contacted by telephone.

        Exclusion Criteria:

          1. Known diagnosis of reproductive tract abnormalities.

          2. Prior pelvic radiation therapy, any malignancy or active pelvic inflammatory disease.

          3. Known history of severe Pelvic Inflammatory Disease (PID).

          4. Prior hysterectomy or non-hysteroscopic myomectomy.

          5. Prior pelvic prolapse surgery using synthetic mesh.

          6. Cervical hypertrophy where D-C &gt; 4 cm (i.e., cervix longer than 4 cm)

          7. Pathological PAP in the past year.

          8. Moderate or severe bacterial cervicitis.

          9. Known overt or occult stress incontinence.

         10. Moderate or severe pelvic pain (&gt; 3 on VAS).

         11. Severe morbid obesity (BMI &gt;40).

         12. Temperature &gt; 38°C (oral or equivalent), sepsis, or active infection requiring IV
             anti-microbial treatment.

         13. Significant cognitive impairment.

         14. Active malignancy other than non-melanoma skin cancer.

         15. Planned surgery (more than a minor one) in the next 30 days.

         16. Patient has a known hypersensitivity to device materials (Nickel, suture material).

         17. Moribund patient or patient with severe or deteriorating damage in critical body
             systems.

         18. Any condition that in the judgment of the investigators would interfere with the
             subject's ability to provide informed consent, comply with study instructions, place
             the subject at increased risk, or which might confound interpretation of study
             results.

         19. Concurrent enrollment in another device or drug trial that has not completed the
             primary endpoint or clinically interferes with the current study endpoints.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Must have uterine prolapse</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Leiter, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MAXIS Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Garner, M.B.A.</last_name>
    <phone>+1-215-940-8178</phone>
    <email>debbie@pop-medical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Marshall, M.A.</last_name>
    <phone>+49-69-2400-3626</phone>
    <email>MaxisOperations@maxismedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Tanjutco, M.D.</last_name>
      <phone>202-877-5811</phone>
      <email>Patricia.Tanjuctco@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Andrew I Sokol, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert E Gutman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheryl B Iglesia, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Josphine Park, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Ann Rcihter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Calvin Killingbeck</last_name>
      <phone>954-659-6247</phone>
      <email>killinc@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Eric Hurtado, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Schachar, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Nassau Community Hospital Cancer Center</name>
      <address>
        <city>Valley Stream</city>
        <state>New York</state>
        <zip>11580</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Surillo</last_name>
      <phone>516-632-3312</phone>
      <email>Surillo@snch.org</email>
    </contact>
    <investigator>
      <last_name>Alan Garely, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salma Rahimi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Female Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Taff</last_name>
      <phone>610-730-2502</phone>
      <email>etaff@fpminstitute.com</email>
    </contact>
    <investigator>
      <last_name>Miles Murphy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincente Lucente, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Bao An Ton, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Schissler, M.S.N., C.R.N.P.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INOVA Women's Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Mishra, M.B.B.S.</last_name>
      <phone>703-776-7140</phone>
      <email>Rashmi.Mishra@inova.org</email>
    </contact>
    <investigator>
      <last_name>S. Abbas Shobieri, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prolapse</keyword>
  <keyword>sacrospinous fixation</keyword>
  <keyword>minimally invasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data a available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

